ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO965

An Integrated Analysis of Safety and Tolerability of Etelcalcetide in Adult Patients on Hemodialysis (HD) with Secondary Hyperparathyroidism (SHPT)

Session Information

  • Patient Safety
    November 03, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Patient Safety

  • 1501 Patient Safety


  • Block, Geoffrey A., Denver Nephrology, Denver, Colorado, United States
  • Chertow, Glenn Matthew, Stanford University School of Medicine, Palo Alto, California, United States
  • Sullivan, John T, Amgen, Thousand Oaks, California, United States
  • Deng, Hongjie, Amgen Inc. , Thousand Oaks, California, United States
  • Mather, Omar, Amgen Inc, Thousand Oaks, California, United States
  • Tomlin, Holly, Amgen Inc. , Thousand Oaks, California, United States
  • Serenko, Michael, Amgen, Thousand Oaks, California, United States

Etelcalcetide (ETL) is a novel, IV calcimimetic for the treatment of SHPT in patients on HD. Here, the safety profile of ETL is summarized.


Safety was assessed by the nature, frequency, and severity of treatment-emergent adverse events (AEs) and changes in lab parameters in the integrated datasets of two 26-week randomized, placebo (PBO)-controlled (PC) studies, a 26-week randomized active-controlled (AC with cinacalcet [CIN]) study, and 2 single-arm open-label extension (OLE) studies. The ETL starting dose was 5 mg 3 times/week (TIW) at the end of HD. Depending on serum PTH and Ca values, the dose could be increased by 2.5 or 5 mg at 4-week intervals to a maximum dose of 15 mg TIW.


841 patients received ETL in the PC (n=503) and AC (n=338) studies and 1289 in the OLE studies for up to 3.4 yr. In the combined dataset of PC studies, common (≥5%) AEs occurring in the ETL group with a ≥1% greater frequency than PBO were blood Ca decrease (63.8% vs 10.1%), muscle spasms (11.5% vs 6.6%), diarrhea (10.7% vs 8.6%), nausea (10.7% vs 6.2%), vomiting (8.9% vs 5.1%), headache (7.6% vs 6.0%), and symptomatic hypocalcaemia (7.0 vs 0.2%). Rates of AEs of interest were similar between ETL and PBO for convulsions (0.8% vs 1.0%), fractures (1.6% vs 2.9%), hypersensitivity (4.4% vs 3.7%), infusion reaction (5.8% vs 5.7%), ventricular tachyarrhythmia (0.4% vs 0.8%), and GI bleeding (2.0% and 2.1%); a small numerical difference was noted in the rate of adjudicated cardiac failure (2.2% vs 1.2%). More patients in the ETL vs PBO groups experienced hypophosphatemia (1.4% vs 0.4%). ETL had no clinically significant effects on blood pressure, heart rate, weight, or hematology lab parameters. No clinically significant differences were observed in the safety profiles of ETL and CIN in the AC study. No new safety signals were identified with long-term ETL exposure in the OLE studies.


Consistent with its mechanism of action, the most important risks associated with ETL were serum Ca reductions and hypocalcemia-related AEs. Integrated safety assessment of ETL across both controlled clinical trials and OLE studies showed an overall favorable risk/benefit profile with no unexpected safety signals.


  • Commercial Support